Sydney Stewart, Author at BioTuesdays

Developments

Study finds invasive prostate cancer incidence rising among young men

The incidence of prostate cancer among adolescents and young adults has increased in the U.S. and many other countries during the past three decades, in direct contrast to older men, according to study results published...

November 20, 2019

Developments

Liminal presents new preclinical data for PBI-4050 on PAH

Liminal BioSciences (NASDAQ:LMNL; TSX:LMNL) presented two scientific posters with new preclinical data for its PBI-4050 drug candidate and the treatment of pulmonary arterial hypertension (PAH) at the American Heart...

November 19, 2019

Markets

SVB Leerink cuts ResTORbio to MP; PT to $2 from $40

SVB Leerink downgraded ResTORbio (NASDAQ:TORC) to “market perform” from “outperform” and slashed its price to $2 from $40 after a failure of first of the company’s two ongoing Phase 3 trials in respiratory infection...

November 15, 2019

Markets

Roth starts Bicycle Therapeutics at buy; PT $17

Roth Capital Partners launched coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $17 price target. The stock closed at $8.61 on Nov. 13. Bicycle is developing peptides that may be able to deliver a...

November 14, 2019

Markets

BTIG hikes Cerus to buy with $7 PT

BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...

November 13, 2019

Developments

Liminal BioSciences presents new preclinical data at ASN Kidney Week

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) and its collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American...

November 11, 2019

Executive Moves

Vireo Health names Bruce Linton as executive chairman

Vireo Health International (CNSX:VREO; OTCQX:VREOF) appointed Bruce Linton to the role of executive chairman, where he will serve as a director, work closely with Vireo CEO and founder, Dr. Kyle Kingsley, and spearhead...

November 7, 2019

Markets

Roth starts Hepion Pharma at buy; PT $9

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6. “Hepion brings a laser focus on liver disease, combined with...

November 7, 2019

Developments

BDC spinout, Amplitude Ventures, launches $200-million life sciences venture fund

Amplitude Ventures of Montreal has launched a $200-million venture fund, closing more than 50% of its target. Amplitude is a spinout of the Business Development Bank of Canada, which is a cornerstone investor in...

November 7, 2019

Developments

Liminal BioSciences to sell bioseparations division to KKR

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) signed a binding share purchase agreement for the proposed saleof its Isle of Man-based bioseparations business operated through subsidiary Prometic Bioseparations (PBL) to...

November 4, 2019

Author - Sydney Stewart

Study finds invasive prostate cancer incidence rising among young men

Liminal presents new preclinical data for PBI-4050 on PAH

SVB Leerink cuts ResTORbio to MP; PT to $2 from $40

Roth starts Bicycle Therapeutics at buy; PT $17

BTIG hikes Cerus to buy with $7 PT

Liminal BioSciences presents new preclinical data at ASN Kidney Week

Vireo Health names Bruce Linton as executive chairman

Roth starts Hepion Pharma at buy; PT $9

BDC spinout, Amplitude Ventures, launches $200-million life sciences venture fund

Liminal BioSciences to sell bioseparations division to KKR

Subscribe